References
- Ainai A, Suzuki T, Tamura SI, et al. (2017). Intranasal administration of whole inactivated influenza virus vaccine as a promising influenza vaccine candidate. Viral Immunol 30:451–62.
- Amorij JP, Saluja V, Petersen AH, et al. (2007). Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice. Vaccine 25:8707–17.
- Bienenstock J. (1980). Bronchus-associated lymphoid tissue and the source of immunoglobulin-containing cells in the mucosa. Environ Health Perspect 35:39–42.
- Chen JR, Liu YM, Tseng YC, et al. (2020). Better influenza vaccines: an industry perspective. J Biomed Sci 27:11.
- Du X, Xiong L, Dai S, et al. (2015). γ-PGA-coated mesoporous silica nanoparticles with covalently attached prodrugs for enhanced cellular uptake and intracellular GSH-responsive release. Adv Healthc Mater 4:771–81.
- Firacative C, Gressler AE, Schubert K, et al. (2018). Identification of T helper (Th)1- and Th2-associated antigens of cryptococcus neoformans in a murine model of pulmonary infection. Sci Rep 8:14.
- Giri PK, Sable SB, Verma I, et al. (2005). Comparative evaluation of intranasal and subcutaneous route of immunization for development of mucosal vaccine against experimental tuberculosis. FEMS Immunol Med Microbiol 45:87–93.
- Horiguchi M, Oiso Y, Sakai H, et al. (2015). Pulmonary administration of phosphoinositide 3-kinase inhibitor is a curative treatment for chronic obstructive pulmonary disease by alveolar regeneration. J Control Release 213:112–9.
- Huber VC, McKeon RM, Brackin MN, et al. (2006). Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 13:981–90.
- Ito R, Ozaki YA, Yoshikawa T, et al. (2003). Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia. Vaccine 21:2362–71.
- Kopf M, Schneider C, Nobs SP. (2015). The development and function of lung-resident macrophages and dendritic cells. Nat Immunol 16:36–44.
- Kurosaki T, Kitahara T, Fumoto S, et al. (2009). Ternary complexes of pDNA, polyethylenimine, and gamma-polyglutamic acid for gene delivery systems. Biomaterials 30:2846–53.
- Kurosaki T, Kitahara T, Nakamura T, et al. (2012). Development of effective cancer vaccine using targeting system of antigen protein to APCs. Pharm Res 29:483–9.
- Marple B, Roland P, Benninger M. (2004). Safety review of benzalkonium chloride used as a preservative in intranasal solutions: an overview of conflicting data and opinions. Otolaryngol Head Neck Surg 130:131–41.
- McKee AS, Munks MW, Marrack P. (2007). How do adjuvants work? Important considerations for new generation adjuvants. Immunity 27:687–90.
- Pittman M. (1991). History of the development of pertussis vaccine. Dev Biol Stand 73:13–29.
- Prodhomme EJ, Tutt AL, Glennie MJ, et al. (2003). Multivalent conjugates of poly-gamma-D-glutamic acid from Bacillus licheniformis with antibody F(ab') and glycopeptide ligands. Bioconjug Chem 14:1148–55.
- Schroeder HW, Jr., Cavacini L. (2010). Structure and function of immunoglobulins. J Allergy Clin Immunol 125:S41–S52.
- Tamura S, Samegai Y, Kurata H, et al. (1988). Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. Vaccine 6:409–13.
- White RT. (1988). Pneumococcal vaccine. Thorax 43:345–8.
- Williams BG, Gouws E, Boschi–Pinto C, et al. (2002). Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis 2:25–32.
- Ye H, Jin L, Hu R, et al. (2006). Poly (γ, l-glutamic acid)–cisplatin conjugate effectively inhibits human breast tumor xenografted in nude mice. Biomaterials 27:5958–65.